Related Experiment Video

Updated: Jan 5, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K

Acquired Factor V Deficiency Associated with CFPM Administration

Masayoshi Yamanishi, Yurika Nishimi, Masakatsu Usui

    Clinical Laboratory
    |October 19, 2019
    PubMed
    Abstract

    Insights

    A rare case of acquired factor V deficiency (AFVD) occurred in an elderly patient undergoing hemodialysis after cefepime administration. This highlights cefepime as a potential trigger for FV inhibitor development.

    Area of Science:

    • Hematology
    • Pharmacology
    • Internal Medicine

    Background:

    • Acquired factor V deficiency (AFVD) is a rare bleeding disorder caused by Factor V (FV) inhibitors.
    • It presents with prolonged clotting times and can range from asymptomatic to severe bleeding.
    • Various factors have been implicated as triggers for FV inhibitors.

    Observation:

    • An 84-year-old male on hemodialysis developed subcutaneous hemorrhage post-cefepime treatment for bacteremia.
    • Laboratory tests revealed severely deficient FV activity (< 1.0%) and a high FV inhibitor titer (9 BU/mL).

    Findings:

    • The patient was diagnosed with acquired factor V deficiency.
    • Cefepime was identified as the likely trigger for the FV inhibitor, despite other potential risk factors.
    • Treatment with oral prednisolone was initiated.

    Implications:

    • This case underscores the potential for cefepime to induce FV inhibitors, even in patients with multiple comorbidities.
    • Early recognition and management of AFVD are crucial.
    • Further research is needed to elucidate the mechanisms linking antibiotics to FV inhibition.

    More Related Videos

    Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes12:24

    Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

    Published on: June 3, 2014

    12.7K
    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice08:13

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

    Published on: September 30, 2021

    7.2K

    Related Concept Videos

    Cystic Fibrosis: Management01:24

    Cystic Fibrosis: Management

    Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
    Sinus disease and chronic...
    426
    Cystic Fibrosis: Pathogenesis01:23

    Cystic Fibrosis: Pathogenesis

    Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
    CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
    674
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    1.6K
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    251
    Disorders of Hemostasis01:24

    Disorders of Hemostasis

    Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
    Thromboembolic Disorders
    Two factors primarily cause thromboembolic conditions.
    1.9K
    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    2.0K